TY  - GEN
AU  - Hodi,F Stephen
AU  - Corless,Christopher L
AU  - Giobbie-Hurder,Anita
AU  - Fletcher,Jonathan A
AU  - Zhu,Meijun
AU  - Marino-Enriquez,Adrian
AU  - Friedlander,Philip
AU  - Gonzalez,Rene
AU  - Weber,Jeffrey S
AU  - Gajewski,Thomas F
AU  - O'Day,Steven J
AU  - Kim,Kevin B
AU  - Lawrence,Donald
AU  - Flaherty,Keith T
AU  - Luke,Jason J
AU  - Collichio,Frances A
AU  - Ernstoff,Marc S
AU  - Heinrich,Michael C
AU  - Beadling,Carol
AU  - Zukotynski,Katherine A
AU  - Yap,Jeffrey T
AU  - Van den Abbeele,Annick D
AU  - Demetri,George D
AU  - Fisher,David E
TI  - Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin
SN  - 1527-7755
PY  - 2013///1122
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Benzamides
KW  - Biomarkers, Tumor
KW  - genetics
KW  - Chronic Disease
KW  - Female
KW  - GTP Phosphohydrolases
KW  - Gene Amplification
KW  - Humans
KW  - Imatinib Mesylate
KW  - Male
KW  - Melanoma
KW  - drug therapy
KW  - Membrane Proteins
KW  - Middle Aged
KW  - Mucous Membrane
KW  - drug effects
KW  - Mutation
KW  - Neoplasm Recurrence, Local
KW  - Piperazines
KW  - Prognosis
KW  - Proto-Oncogene Mas
KW  - Proto-Oncogene Proteins c-kit
KW  - Pyrimidines
KW  - Skin Neoplasms
KW  - Sunlight
KW  - Survival Rate
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2012.47.7836
ER  -